Our business is regulated by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry which sets out the requirements our industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner. The Code includes requirements for how we may work with healthcare professionals, healthcare organisations and patient organisations and in recent years it has introduced new requirements for greater transparency in these areas. In May 2023, our UK Country President, Susan Rienow, was appointed President of the ABPI to help oversee the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA).
We strongly support the work the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the ABPI have done to move towards greater transparency across the pharmaceutical industry.
Working with healthcare professionals and healthcare organisations helps us to deliver the best results for patients.
Pfizer is committed to being transparent about the relationships we have with other organisations.
We believe transparency is essential when working with patient organisations.
Find out how much we have given to third party research and development activities in the UK.